Use of vemurafenib in a patient unable to swallow whole

Area of Science:

• Oncology
• Pharmacology
• Dermatology

Background:

• Metastatic melanoma treatment has advanced with targeted therapies.
• Activating BRAF mutations are common in melanoma, leading to targeted therapies like vemurafenib.
• Vemurafenib is a selective BRAF Val600 inhibitor demonstrating efficacy in metastatic melanoma.

Observation:

• A 38-year-old woman with metastatic BRAFV600E melanoma presented with severe tablet phobia.
• The patient was observed to be crushing and/or chewing her vemurafenib tablets.
• This administration method deviated from standard oral tablet intake.

Findings:

• Despite altered administration, the patient achieved a partial response to vemurafenib.
• Significant clinical benefit was noted, although it was temporary.
• The findings suggest potential for alternative drug delivery methods in specific patient populations.

Implications:

• This case suggests that altered administration of vemurafenib may yield clinical benefit in patients with administration challenges.
• It underscores the importance of considering patient-specific factors, such as phobias, in treatment adherence.
• Further investigation into alternative formulations or administration techniques for BRAF inhibitors may be warranted.